Financhill
Back

RAPT Therapeutics Quote, Financials, Valuation and Earnings

Sell
11

RAPT
RAPT Therapeutics

Last Price:
3.97
Seasonality Move:
56.89%

7 Day Trial

ALL ACCESS PASS

$ 7

RAPT Therapeutics Price Quote

$3.97
-0.07 (-1.73%)
(Updated: May 20, 2024 at 3:40 PM ET)

RAPT Therapeutics Key Stats

Sell
11
RAPT Therapeutics (RAPT) is a Sell

Day range:
$4.03 - $4.23
52-week range:
$3.98 - $27.35
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
47.78
P/B ratio:
1.08%

Volume:
542.3K
Avg. volume:
1M
1-year change:
-80.81%
Market cap:
$141M
Revenue:
$0
EPS:
$-3.08

How Much Does RAPT Therapeutics Make?

Data Unavailable

Is RAPT Therapeutics Growing As A Company?

Data Unavailable

RAPT Therapeutics Stock Price Performance

  • Did RAPT Therapeutics Stock Go Up Last Month?
    RAPT Therapeutics share price went down by -49.75% last month
  • Did RAPT's Share Price Rise Over The Last Year?
    RAPT share price fell by -80.81% over the past 1 year

What Is RAPT Therapeutics 52-Week High & Low?

RAPT Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy RAPT Therapeutics?

  • How Much Debt Does RAPT Therapeutics Have?
    Total long term debt quarterly is $0
  • How Much Cash Does RAPT Therapeutics Have?
    Cash and short term investments quarterly total is $141.6M
  • What Is RAPT Therapeutics’s Book Value Per Share?
    Book value per share is 3.75

Is RAPT Therapeutics Cash Flow Positive?

  • What Is RAPT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$105.5M
  • What Is RAPT Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $10.4M
  • What Is RAPT Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $94.7M

RAPT Therapeutics Return On Invested Capital

Data Unavailable

RAPT Therapeutics Earnings Date & Stock Price

RAPT Therapeutics Competitors

  • Who Are RAPT Therapeutics's Competitors?
    Below is a list of companies who compete with RAPT Therapeutics or are related in some way:
    • Avinger Inc (AVGR)
    • Axsome Therapeutics Inc (AXSM)
    • Emergent BioSolutions Inc (EBS)
    • Skye Bioscience Inc (SKYE)
    • Tonix Pharmaceuticals Holding Corp (TNXP)

RAPT Therapeutics Dividend Yield

Data Unavailable

RAPT Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 3.05%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 3
Hold Recommendations: 8
Sell Recommendations: 0
Price Target: 14.57
Upside from Last Price: 260.68%

Major Shareholders

  • How many RAPT shares are owned by institutional investors?
    57.2M RAPT shares are owned by institutional investors
  • How many RAPT shares are owned by insiders?
    245.6K RAPT shares are owned by insiders